Table 2 Clinical trials of CAR-Treg, CAR-γδT, CAR-NKT, CAR-NK, CAR-M and iCARs
| Â | NCT | Cell source | Target | Cancer | Phase | Status | Location |
|---|---|---|---|---|---|---|---|
Treg [3] | NCT05114837 | Treg | CD19 | ALL | I/II | Not yet recruiting | US |
NCT04817774 | Treg | HLA-A2 | Renal Transplant Rejection | I/II | Recruiting | Europe | |
NCT05234190 | Treg | HLA-A2 | Liver Transplant Rejection | I/II | Recruiting | UK | |
γδT cells [7] | NCT02656147 | γδT | CD19 | B-cell Lymphoma, ALL, CLL | I | Unknown | China |
NCT05554939 | γδT | CD19 | NHL | I/II | Recruiting | China | |
NCT04735471 | γδT | CD20 | B-cell Malignancies | I | Recruiting | US | |
NCT04702841 | γδT | CD7 | T-cell Malignancies | Early I | Recruiting | China | |
NCT05388305 | γδT | CD123 | AML | NA | Recruiting | China | |
NCT04796441 | γδT | CD123 | AML | NA | Recruiting | China | |
NCT04107142 | γδT | NKG2DL | Solid Tumors | I | Unknown | Malaysia | |
NKT cells [5] | NCT05487651 | NKT | CD19 | B-cell Malignancies | I | Recruiting | US |
NCT03774654 | NKT | CD19 | B-cell Malignancies | I | Recruiting | US | |
NCT00840853 | NKT | CD19 | ALL, NHL | I | Active, Not recruiting | US | |
NCT04814004 | NKT | CD19 | B-cell Malignancies | I | Recruiting | China | |
NCT03294954 | NKT | GD2 | Neuroblastoma | I | Active, Not recruiting | US | |
NK cells [48] | NCT00995137 | PB NK | CD19 | ALL | I | Completed | US |
NCT05020678 | PB NK | CD19 | B-cell Malignancies | I | Recruiting | US | |
NCT03824964 | PB NK | CD19/22 | B-cell Lymphoma | Early I | Unknown | Unknown | |
NCT03692767 | PB NK | CD22 | B-cell Lymphoma | Early I | Unknown | Unknown | |
NCT04623944 | PB NK | NKG2DL | AML, MDS | I | Recruiting | US | |
NCT03415100 | PB NK | NKG2DL | Metastatic Solid Tumors | I | Unknown | China | |
NCT03692637 | PB NK | Mesothelin | Epithelial Ovarian Cancer | Early I | Unknown | Unknown | |
NCT02944162 | NK-92 | CD33 | AML | I/II | Unknown | China | |
NCT02742727 | NK-92 | CD7 | Leukemia, Lymphoma | I/II | Unknown | China | |
NCT02892695 | NK-92 | CD19 | Leukemia, Lymphoma | I/II | Unknown | China | |
NK cells [48] | NCT03690310 | NK-92 | CD19 | B-cell Lymphoma | Early I | Unknown | Unknown |
NCT03692663 | NK-92 | PSMA | Prostate Cancer | Early I | Recruiting | China | |
NCT03940833 | NK-92 | BCMA | MM | I/II | Unknown | China | |
NCT02839954 | NK-92 | MUC1 | Solid Tumors | I/II | Unknown | China | |
NCT03940820 | NK-92 | ROBO1 | Solid Tumors | I/II | Unknown | China | |
NCT03931720 | NK-92 | ROBO1 | Malignant Tumor | I/II | Unknown | China | |
NCT03941457 | NK-92 | ROBO1 | Pancreatic Cancer | I/II | Unknown | China | |
NCT05528341 | NK-92 | NKG2DL | Solid Tumors | I | Recruiting | China | |
NCT03383978 | NK-92 | HER2 | Glioblastoma | I | Recruiting | Germany | |
NCT03656705 | NK-92 | PD-L1 | Advanced NSCLC | I | Recruiting | China | |
NCT04050709 | NK-92 | PD-L1 | Advanced Solid Cancers | I | Active, Not recruiting | US | |
NCT04847466 | NK-92 | PD-L1 | GEJ Cancers, HNSCC | II | Recruiting | US | |
NCT04796675 | CB NK | CD19 | B-Lymphoid Malignancies | I | Recruiting | China | |
NCT03056339 | CB NK | CD19 | B-Lymphoid Malignancies | I/II | Active, Not recruiting | US | |
NCT05472558 | CB NK | CD19 | NHL | I | Recruiting | China | |
NCT05667155 | CB NK | CD19/CD70 | NHL | I | Not yet recruiting | China | |
NCT05092451 | CB NK | CD70 | AML, MDS, B-cell Lymphoma | I/II | Recruiting | US | |
NCT05110742 | CB NK | CD5 | Hematological Malignances | I/II | Not yet recruiting | US | |
NCT05008536 | CB NK | BCMA | MM | Early I | Recruiting | China | |
NCT05673447 | Unknown | CD19 | DLBCL | Early I | Not yet recruiting | Unknown | |
NCT05645601 | Unknown | CD19 | B-cell Malignancies | I | Recruiting | China | |
NCT04639739 | Unknown | CD19 | NHL | Early I | Not yet recruiting | China | |
NCT04887012 | Unknown | CD19 | NHL | I | Recruiting | China | |
NCT05654038 | Unknown | CD19 | B-cell Malignancies | I/II | Recruiting | China | |
NCT05410041 | Unknown | CD19 | B-cell Malignancies | I | Recruiting | China | |
NK cells [48] | NCT05336409 | Unknown | CD19 | B-cell Malignancies | I | Recruiting | US |
NCT05563545 | Unknown | CD19 | ALL | I | Completed | China | |
NCT04796688 | Unknown | CD19 | B-cell Malignancies | I | Recruiting | China | |
NCT05652530 | Unknown | BCMA | MM | Early I | Recruiting | China | |
NCT05008575 | Unknown | CD33 | AML | I | Recruiting | China | |
NCT05215015 | Unknown | CD33/CLL1 | AML | Early I | Recruiting | China | |
NCT05574608 | Unknown | CD123 | AML | Early I | Recruiting | China | |
NCT05247957 | Unknown | NKG2DL | AML | NA | Terminated | China | |
NCT05213195 | Unknown | NKG2DL | Metastatic Colorectal Cancer | I | Recruiting | China | |
NCT05507593 | Unknown | DLL3 | SCLC | I | Recruiting | China | |
NCT05410717 | Unknown | CLDN6 | Advanced Solid Tumors | I/II | Recruiting | China | |
NCT05137275 | Unknown | 5T4 | Advanced Solid Cancers | Early I | Recruiting | China | |
NCT05194709 | Unknown | 5T4 | Advanced Solid Tumors | Early I | Recruiting | China | |
Macrophages [1] | NCT04660929 | Macrophages | HER2 | Solid Tumors | I | Recruiting | US |
iPSCS [5] | NCT04629729 | FT819 | CD19 | B-cell Lymphoma, ALL, CLL | I | Recruiting | US |
NCT05182073 | FT576 | BCMA | MM | I | Recruiting | US | |
NCT04245722 | FT596 | CD19 | B-cell Lymphoma, CLL | I | Recruiting | US | |
NCT04555811 | FT596 | CD19 | NHL, DLBCL, B-cell Lymphoma | I | Recruiting | US | |
NCT03824951 | iPSCs | CD19 | B-cell Lymphoma | Early I | Unknown | Unknown |